Erlotinib and Gemcitabine in Treating Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline and/or a Taxane
Study Information
Alliance Study ID: NCCTG-N0234
NCT Study ID (ClinicalTrials.gov): NCT00059852
Disease or Cancer Type: Breast Cancer
Alliance Study Chair: Edith A. Perez, MD
Status: COMPLETED
Study Description
RATIONALE: Drugs used in chemotherapy such as gemcitabine work in different ways to stop tumor cells from dividing so they stop growing or die. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Combining gemcitabine with erlotinib may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining gemcitabine with erlotinib in treating patients who have metastatic breast cancer that has been previously treated with an anthracycline and/or a taxane.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information